Enter your search terms:


Aquestive Therapeutics Announces Closing of Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering

WARREN, N.J., Aug. 15, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced the underwriters of its previously announced initial public offering of common stock have partially exercised their over-allotment option to...

Court Ruling in Favor of Aquestive Therapeutics Enjoining Dr. Reddy’s Laboratories from Launching its Generic Suboxone Product

WARREN, N.J., July 16, 2018 /PRNewswire/ -- Aquestive Therapeutics ("Aquestive") announces today that the U.S. District Court for the District of New Jersey has granted Aquestive together with Indivior PLC (LON: INDV) and its U.S. subsidiary, Indivior Inc., a preliminary injunction against Dr. Reddy's Laboratories ("DRL"), mandating the restrictions...

Aquestive Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Clobazam Oral Soluble Film to Treat Lennox-Gastaut Syndrome

WARREN, N.J., January 18, 2018 – Aquestive Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application for clobazam Oral Soluble Film (clobazam OSF) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)...



The first and only FDA approved film formulation of clobazam.

Click here to learn more Please see full prescribing information, including BOXED WARNING